bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.04.17.719238

EasyCAPS: A web tool for restriction-based genotyping and rational CRISPR-Cas9 donor design

Abstract

Tracking Single Nucleotide Polymorphisms (SNPs) following CRISPR-Cas9 genome editing is a critical yet often labor-intensive step in modern genetic research. Although Sanger sequencing is the conventional method for definitive confirmation, it typically requires substantial time to generate results. In contrast, PCR-based restriction methods like CAPS (Cleaved Amplified Polymorphic Sequence) and dCAPS (derived CAPS) offer rapid and cost-effective alternatives. However, existing dCAPS primer design tools suffer from significant limitations and were largely developed for tracking polymorphisms in plant genomes. Concurrently, CRISPR-Cas9 gene editing requires strategies to prevent the re-cleavage of the edited allele, typically involving the modification of the Protospacer Adjacent Motif (PAM). To address these challenges, we developed EasyCAPS, a web-based tool that integrates dCAPS primer design with advanced functionalities for CRISPR experiments. EasyCAPS overcomes the shortcomings of previous software by enabling restriction enzyme pre-selection and optimizing designs for complex DNA sequences. Its key innovation is the "Hiding PAM" feature, which designs synonymous mutations to mask the Cas9 recognition site while accounting for codon usage bias, thereby facilitating one-step allelic exchange. The utility of the tool was demonstrated through practical applications targeting the HTA1, PHO84, and CAT5 genes, significantly accelerating both genotyping and gene editing processes. We conclude that EasyCAPS is an accessible solution that effectively streamlines molecular biology workflows.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

de Bem, L. S., Gross, J., Jacobus, A. P.. 2026-04-18. EasyCAPS: A web tool for restriction-based genotyping and rational CRISPR-Cas9 donor design. https://doi.org/10.64898/2026.04.17.719238

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

OPA1 controls mitochondrial dysfunction-driven liver fibrosis in MASLD

Progressive hepatic fibrosis is the principal determinant of morbidity and mortality in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). Mitochondrial dysfunction is a hallmark of MASH, and the release of mitochondrial damage-associated molecular patterns (mito-DAMPs) from injured hepatocytes can promote fibrosis. However, how mitochondrial dynamics and quality control shape the fibrotic response in MASLD/MASH remains unclear. Here, through large-scale genomic analyses of mitochondrial genes governing mitophagy, fusion and fission in human MASLD, with a power-equivalent sample size of approximately 700,000 individuals, we identify a strong association between hepatic fibrosis and the mitochondrial fusion factor dynamin-like GTPase optic atrophy 1 (OPA1). OPA1 transcripts and protein abundance in the liver epithelium were progressively dysregulated with advancing fibrosis. In mice, hepatocyte-specific OPA1 loss alone was sufficient to induce hepatic stellate cell activation and fibrosis in zone 3, promoted the release of mito-DAMPs into the circulation and exacerbated fibrosis in experimental MASH. These findings identify OPA1 as a central regulator of the hepatic fibrotic response and connect defective mitochondrial homeostasis to mito-DAMP release, hepatic stellate cell activation and fibrosis in MASLD.

genetics↗

Temporal control of mitochondrial mutagenesis reveals the fate of mtDNA mutations with age

Mutations in the mitochondrial genome (mtDNA) play a critical role in the aging process and a wide variety of age-related diseases. However, it remains unclear when the mutations that drive physiological decline arise. To answer this question, we generated a new mouse model in which mitochondrial mutagenesis can be confined to a defined window of time. Surprisingly, we found that mutations that arise during the first two months of life are sufficient to drive a wide variety of age-related pathologies, and that the severity of this pathology is broadly regulated by distinct, tissue-specific selective pressures that control the fate of mtDNA mutations with age. Further, we found that selection against deleterious variants can be modulated by manipulation of mitochondrial fusion in vitro and in vivo. These observations raise the possibility that in some tissues, the pace of aging is pre-determined by events that occur early in life and that interventions targeting mitochondrial fusion may be able to slow down or reverse the expansion of these pathogenic variants. These results carry far-reaching implications for strategies aimed at preventing or delaying age-related decline.

genetics↗

Innate immune stress pathway activation underlies heterochromatin dysfunction pathology

Heterochromatin loss disrupts nuclear architecture, gene regulation and repetitive element silencing, and is associated with diverse human diseases. However, mechanisms linking heterochromatin dysfunction to pathological phenotypes remain unclear. Using genetic interaction screening and genomic analyses in C. elegans, we identify secondary activation of the Intracellular Pathogen Response (IPR), an innate immune stress pathway, as a major contributor to heterochromatin mutant phenotypes. Constitutive IPR activation phenocopies slow growth and indirect transcriptional changes observed in these mutants. Depletion of genetic enhancers further increased, whereas suppressor RNAi attenuated IPR activation, with direct heterochromatin targets remaining substantially deregulated. Notably, many suppressors encode active chromatin components, and mild reduction of RNA polymerase II activity ameliorates growth defects in C. elegans HP1 mutants and human HP1-deficient cells. Our findings reveal secondary stress response activation as an important mechanism linking heterochromatin dysfunction to pathology and identify transcriptional dampening as a potential therapeutic strategy for mitigating these effects.

genetics↗